Evidence map›Paper›PMID 39623509›Full record

ArticleImplementation science communications2024

A qualitative study of perceptions of the care pathway for familial hypercholesterolemia: screening, diagnosis, treatment, and family cascade screening.

Amy R Pettit, Tamar Klaiman, Rebecca Connelly Kersting, Christina Johnson, Nkiru Ogbuefi, Maeve Moran, Krystin Sinclair, Jenna Steckel, Laurie Norton, Jennifer A Orr and 7 more

Abstract read
In one paragraph

Article in Implementation science communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Amy R PettitIndependent Consultant, Boston, MA, USA.ORCID http://orcid.org/0009-0008-0115-8412
Tamar KlaimanPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-8718-5674
Rebecca Connelly KerstingPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Christina JohnsonFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0009-0009-1747-2999
Nkiru OgbuefiFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Maeve MoranPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-9675-5488
Krystin SinclairPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jenna SteckelPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Laurie NortonPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jennifer A OrrPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-7612-2432
Adina LiebermanPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0009-0002-2498-561X
Mary P McGowanGeisel School of Medicine at Dartmouth, Hanover, NH, USA.ORCID http://orcid.org/0000-0001-5761-9267
Eric TricouFamily Heart Foundation, Fernandina Beach, FL, USA.ORCID http://orcid.org/0000-0002-8098-1990
Jinbo ChenPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-3174-2552
Daniel J RaderPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-9245-9876
Kevin G VolppPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-3389-6707
Rinad S BeidasFeinberg School of Medicine, Northwestern University, Chicago, IL, USA. rinad.beidas@northwestern.edu.ORCID http://orcid.org/0000-0001-6056-6071

Funding

U.S. Department of Defense W81XWH-21-1-0420U.S. Department of Defense W81XWH-21-1-0421
6 · The paper itself

Abstract

backgroundFamilial hypercholesterolemia (FH) is an autosomal dominant genetic condition that carries increased risk for premature atherosclerotic cardiovascular disease, cardiovascular events, and death. Due to low uptake of evidence-based practices, up to 80% of FH patients remain undiagnosed and most are undertreated. This project aimed to understand patient and clinician perceptions across the care pathway of evidence-based diagnosis and treatment of FH, to inform implementation strategy design for two clinical trials seeking to increase evidence-based care.

methodsWith input from FH experts, we identified key points along the FH care pathway that might be targeted with broad-scale implementation efforts, including: (a) identification of the need for screening; (b) completion of screening test(s); (c) diagnosis; (d) connection to treatment; and (e) family cascade screening (a process used to identify and screen relatives of individuals diagnosed with FH). Then, we conducted qualitative interviews with patients who had participated in a prior FH quality improvement initiative and with clinicians who treat high cholesterol. We analyzed data using thematic analysis.

resultsWe interviewed 21 patients and 17 clinicians. Patient themes offered insights related to the impact of family history, reactions to a diagnosis of high cholesterol and/or FH, experiences with FH treatment and clinical care, perceptions of tools to diagnose FH, motivations and preferences for FH screening efforts, and reactions to family screening. Clinician themes offered insights into the perceived value of FH screening and diagnosis, current FH-related practice and context, and attitudes toward tools to aid clinical practice. In both sets of interviews, confusion and misconceptions about what makes FH unique and its clinical implications were common, as were concerns about logistics and competing priorities.

conclusionQualitative inquiry generated insights into several modifiable patient and clinician determinants of engagement with evidence-based implementation along the FH care pathway, many of which can be targeted with behavioral economics strategies that simplify complex decisions and by addressing informational and emotional needs. These findings offer actionable insights to inform future implementation research that seeks to close the evidence-to-practice gap in diagnosis and delivery of evidence-based care for FH.

Indexed as

Barriers to careCare pathwayCascade screeningFamilial hypercholesterolemiaFIND FHImplementation scienceMachine learningUnderdiagnosis

Identifiers

PMID39623509
PMCPMC11613662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.